Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 64Years
All Genders
ID05630235

Effects of a Hemp-derived Cannabidiol and Cannabidiolic-acid Oral Extract on Resting-state Electroencephalography and Neuropathic Pain Symptoms in People With Spinal Cord Injury

Led by University of Miami · Updated on 2025-06-17

20

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University of Miami

Lead Sponsor

C

Consortium for Medical Marijuana Clinical Outcomes Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying the effects of a hemp-derived oral extract containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) on neuropathic pain symptoms and brain electrical activity in people with spinal cord injury (SCI). The study aims to measure changes in pain intensity, unpleasantness, and skin sensitivity to hot and cold temperatures, as well as changes in brain activity using electroencephalography (EEG). Participants receive either a one-time oral dose of 204.6 mg of CBD/CBD-A or a placebo in a randomized, double-blind design. One group receives CBD/CBD-A first followed by placebo after two weeks, while the other group receives placebo first followed by CBD/CBD-A after two weeks. This crossover design allows comparison of the extract's effects against placebo within the same participants. During the study, participants will be assessed at baseline and then approximately 3 and 6 hours after each intervention. Evaluations include neuropathic pain intensity and unpleasantness, brain EEG activity, sensory function tests, anxiety levels, and subjective drug effects. This detailed monitoring helps researchers understand the short-term impact of CBD/CBD-A on pain and brain function in individuals with SCI-related neuropathic pain.

CONDITIONS

Brief Title

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

Who Can Participate

Age: 18Years - 64Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men or women aged 18 to 64 years
  • Have an incomplete or complete acquired traumatic spinal cord injury
  • Experience neuropathic pain for at least three months before joining the study
  • Have moderate to severe pain intensity, scoring at least 4 on a 0 to 10 scale
  • Have previous experience with consuming cannabis or cannabinoids
Not Eligible

You will not qualify if you...

  • Current drug abuse (DAST-10 score above 6) or alcohol abuse (AUDIT score above 10)
  • Currently using cannabis products (CBD or CBD+THC), other drugs of abuse, or alcohol unless prescribed
  • Have significant medical illnesses such as diabetes, obesity, cardiovascular disease, hypertension, or hepatitis
  • History or current severe psychiatric disorders including major depression, bipolar disorder, schizophrenia, or PTSD
  • Unable to consent, pregnant, breastfeeding, not using effective birth control, or prisoner
  • Current pregnancy or not using two forms of effective birth control if of childbearing potential
  • History of kidney or liver disease
  • Elevated liver enzymes or bilirubin above normal limits
  • Taking valproate or strong CYP2C19 and CYP3A4 inducers
  • Suicidal thoughts
  • Cannot abstain from alcohol during the study
  • Known allergy to cannabidiol, tetrahydrocannabinol, sesame seed oil, lecithin, or bovine gelatin

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Approximately 4 weeks

Participants receive a one-time oral dose of CBD/CBD-A or placebo, followed by the alternate treatment after a two-week period.

3 visits (in-person)

Trial Site Locations

Total: 1 location

1

Lynn Rehabilitation Center

Miami, Florida, United States, 33136

Actively Recruiting

Loading map...

Research Team

E

Eva Widerstrom-Noga, PhD, DDS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Similar Trials

A Randomized, Double-blind, Placebo-controlled, Multiple-Asc...

Post Herpetic Neuralgia

Actively Recruiting

1 location

A Novel Repetitive Synchronized Associative Stimulation Neur...

SCI - Spinal Cord Injury

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here